Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital Melbourne Vic 3181, Australia ANZIC-RC.
Am J Transplant. 2011 Oct;11(10):2190-6. doi: 10.1111/j.1600-6143.2011.03663.x. Epub 2011 Jul 27.
Early studies reported cytomegalovirus (CMV) pneumonitis as a risk factor for development of bronchiolitis obliterans syndrome (BOS) following lung transplantation. While improvements in antiviral prophylaxis have resulted in a decreased incidence of CMV pneumonitis, molecular diagnostic techniques allow diagnosis of subclinical CMV replication in the allograft. We hypothesized that this subclinical CMV replication was associated with development of BOS. We retrospectively evaluated 192 lung transplant recipients (LTR) from a single center between 2001 and 2009. Quantitative (PCR) analysis of CMV viral load and histological evidence of CMV pneumonitis and acute cellular rejection was determined on 1749 bronchoalveolar lavage (BAL) specimens and 1536 transbronchial biopsies. CMV was detected in the BAL of 41% of LTR and was significantly associated with the development of BOS (HR 1.8 [1.1-2.8], p = 0.02). This association persisted when CMV was considered more accurately as a time-dependent variable (HR 2.1 [1.3-3.3], p = 0.003) and after adjustment for significant covariates in a multivariate model. CMV replication in the lung allograft is common following lung transplantation and is associated with increased risk of BOS. As antiviral prophylaxis adequately suppresses CMV longer prophylactic strategies may improve long-term outcome in lung transplantation.
早期研究报告称巨细胞病毒(CMV)肺炎是肺移植后发生闭塞性细支气管炎综合征(BOS)的危险因素。虽然抗病毒预防措施的改进降低了 CMV 肺炎的发病率,但分子诊断技术可在同种异体移植物中诊断亚临床 CMV 复制。我们假设这种亚临床 CMV 复制与 BOS 的发展有关。我们回顾性评估了 2001 年至 2009 年间来自单一中心的 192 例肺移植受者(LTR)。对 1749 份支气管肺泡灌洗液(BAL)标本和 1536 份经支气管活检标本进行 CMV 病毒载量的定量(PCR)分析和 CMV 肺炎和急性细胞性排斥的组织学证据。在 41%的 LTR 中检测到 BAL 中的 CMV,并且与 BOS 的发展显著相关(HR 1.8 [1.1-2.8],p = 0.02)。当 CMV 被更准确地视为时间依赖性变量(HR 2.1 [1.3-3.3],p = 0.003)并且在多变量模型中调整了重要协变量后,这种关联仍然存在。肺移植后肺同种异体移植物中 CMV 复制很常见,并且与 BOS 的风险增加相关。由于抗病毒预防可充分抑制 CMV,因此预防性策略可能会改善肺移植的长期预后。